VIVJOA Drug Patent Profile

Which patents cover Vivjoa, and what generic alternatives are available?

Vivjoa is a drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-five patent family members in twenty-two countries.

The generic ingredient in VIVJOA is oteseconazole. One supplier is listed for this compound. Additional details are available on the oteseconazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Vivjoa

Vivjoa was eligible for patent challenges on April 26, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 17, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIVJOA

International Patents:	65
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Patent Applications:	61
Drug Prices:	Drug price information for VIVJOA
What excipients (inactive ingredients) are in VIVJOA?	VIVJOA excipients list
DailyMed Link:	VIVJOA at DailyMed

See drug prices for VIVJOA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIVJOA

NDA:

215888

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIVJOA

Drug Class	Azole Antifungal
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors

US Patents and Regulatory Information for VIVJOA

VIVJOA is protected by five US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y

International Patents for VIVJOA

When does loss-of-exclusivity occur for VIVJOA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Lithuania

Mexico

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIVJOA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016233113
Brazil	112017018823
Canada	2978339
China	107428724
Cyprus	1125554
Denmark	3271347
Eurasian Patent Organization	037556

Last updated: June 24, 2026

Vivjoa (vibegron) Market Dynamics and Financial Trajectory: Pricing, Uptake, Exclusivity, and Competitive Pressure

Vivjoa (vibegron) is a branded oral beta-3 adrenergic agonist for overactive bladder. Financial trajectory is shaped by (1) post-launch uptake versus established antimuscarinics and mirabegron, (2) payer and formulary positioning, (3) the launch-and-label expansion of combination and higher-acuity segments, and (4) near-term erosion risk driven by competitive pricing and the absence of high-barrier IP on near-vertical reformulations in the mid-2020s.

How is Vivjoa (vibegron) priced and how do payers position it vs mirabegron?

What are the typical pricing and reimbursement dynamics for oral OAB beta-3 agonists

Vivjoa is positioned as a convenience and tolerability option within overactive bladder (OAB) pharmacotherapy. In market dynamics, beta-3 agonists typically face payer scrutiny around:

• Net price versus mirabegron (alternative beta-3 competitor)
• Formulary tier placement relative to antimuscarinics
• Prior authorization (PA) patterns after initial adoption
• Step therapy versus unrestricted access

From a financial trajectory standpoint, the key driver is whether payers treat Vivjoa as a preferred beta-3 class alternative or as a second-line option after mirabegron. In practice, net sales for newer branded entrants often lag while payers implement reimbursement controls and shift patients to lower-cost class peers.

What payer access hurdles most impact Vivjoa uptake

For oral OAB brands, utilization growth is constrained by:

• Managed care decisions that require trial of at least one OAB agent
• Pharmacy benefit manager (PBM) formulary changes tied to budget impact
• Patient cohort limitations during early months, followed by reassessment at P&T committee cycles

These factors affect revenue ramp timing. Even when clinical adoption is strong, sales growth can flatten when formulary access tightens.

How does Vivjoa compare commercially with mirabegron and antimuscarinics

Mirabegron is usually established as the anchor branded beta-3 comparator, which creates two financial effects:

• Higher baseline payer familiarity and contracting may compress net pricing for Vivjoa
• Switch rates may depend more on copay and formulary placement than on incremental efficacy claims

Antimuscarinics remain the historical default in many formularies. Their lower acquisition cost can pressure Vivjoa to compete through net-to-list discounting rather than premium pricing.

---

When did Vivjoa launch and how does launch timing affect the revenue curve?

What launch milestones determine near-term sales trajectory

Vivjoa’s market curve is driven by standard commercial milestones:

• Initial FDA approval and launch execution
• First-year formulary penetration (preferred vs non-preferred)
• Follow-on label expansions or line-extension impacts on prescribing volume
• Generic and biosimilar risk mapping for adjacent beta-3 molecules

For a mid-term view, the most important revenue-shaping variable is whether Vivjoa reaches and sustains “preferred” status by consecutive formulary committee cycles. If it does not, sales often show early adoption then plateau.

How quickly do new OAB brands typically scale in the US

New OAB entrants commonly scale in phases:

1. Early uptake in targeted prescribers and commercially insured populations
2. Gradual growth as PA and step edits become normalized
3. Slower growth as payer policies mature and competitive contracting tightens

Without barrier-dominant differentiation, the plateau risk is usually connected to formulary tier and net pricing rather than to clinical channel strength alone.

---

What is the patent and exclusivity posture for Vivjoa, and when does exclusivity risk peak?

What patents protect vibegron and what determines generic entry risk

Vivjoa’s competitive threat window is determined by:

• Composition-of-matter (compound) patent term
• Additional patents on formulations, crystalline forms, manufacturing methods, and dosing regimens
• Potential method-of-use coverage (OAB indications, patient subsets)
• Regulatory exclusivities (if applicable) that can delay generic approvals even when patents expire

Generic entry risk peaks when core patents near expiration and Orange Book listings become sparse or easy to design around. For a revenue trajectory, this is where branded net price typically becomes more volatile as launch planning starts for FDA-ready competitors.

How do Orange Book listings translate into revenue exposure

If Orange Book coverage is dense with blocking patents, generics face higher litigation or design-around costs. If coverage is thin beyond core compound protection, generics can enter faster after expiration, usually compressing peak sales and accelerating revenue decay.

---

How many generics or ANDA opportunities exist for Vivjoa, and what are typical Paragraph IV incentives?

What generic entry typically looks like for oral OAB drugs

For oral small molecules in OAB, ANDA competition frequently follows a timeline:

• Filing aligned with patent expiration calendars
• Paragraph IV certifications when potential non-infringement/invalidity arguments exist
• Settlement or continued litigation that shapes the “first generic” launch date

The financial trajectory effect is direct:

• A first generic launch usually changes prescribing behavior through copay and net price changes
• Multiple launches increase competitive pressure and accelerate erosion

What Paragraph IV strategy implies for branded revenues

A dense ANDA field increases the probability of early entrants and drives:

• Faster price competition
• More aggressive payer contracting
• Increased PBM utilization management

Without specific ANDA/Paragraph IV data for Vivjoa in the public record here, the revenue-impact framework remains driven by exclusivity expiration and Orange Book patent structure rather than by confirmed filing intensity.

---

What is the FDA regulatory status of Vivjoa, and does pathway selection affect competitive timelines?

FDA pathway mechanics that shape market timing

For small-molecule drugs, the timing of generics is governed by:

• Patent expiration and Orange Book status
• Any applicable non-patent exclusivities
• ANDA approval timing after successful certification and any required litigation stays

A faster-than-expected generic timeline changes the financial trajectory most through:

• accelerated net pricing pressure
• earlier loss of payer preference
• faster switching at pharmacy counter and through e-prescribing

---

What formulation or delivery patents could extend Vivjoa’s commercial runway?

Which patent types most often protect oral tablet franchises

For oral beta-3 agonists, practical patent extensions often focus on:

• Formulation composition (excipients and specific tablet compositions)
• Solid-state forms and polymorphs
• Manufacturing processes and process controls
• Stability/bioperformance studies used to support formulation patents

If these patents are granted and listed, they can delay generic substitution for specific product configurations, buying time for branded revenue and for payer contracting.

How do formulation patents affect “authorized generic” scenarios

Formulation barriers can reduce authorized generic viability if generic applicants need a protected formulation. That tends to:

• slow generic entry
• preserve some branded pricing power longer
• raise switching costs for payers that rely on interchangeability

---

How does Vivjoa’s competitive landscape affect sales durability (net price, volume, and share)?

Key commercial variables that determine net sales

Vivjoa’s revenue is most exposed to:

• Net price compression (discounting and rebate intensity)
• Volume share shifts among OAB subtypes
• Prescriber switching dynamics between beta-3 agonists and antimuscarinics
• Patient persistence (drug discontinuation reduces lifetime value)

Competitive signals that typically precede revenue inflection

Revenue often changes when any of the following occur:

• Payer downgrades from preferred to non-preferred tier
• Copay program restrictions
• Competitive introductions with better net economics
• Expansion of step-therapy requirements

---

How strong is the patent estate for Vivjoa compared with other OAB brands?

Patent estate strength drivers for market protection

Patent strength, from an investment and licensing lens, is determined by:

• Number of active listed patents at/near expiration
• Breadth of independent claims across formulation, method-of-use, and composition
• Litigation history and record of invalidity or non-infringement
• Remaining term across the key commercial product(s)

If Vivjoa’s estate is comparable to other mature small-molecule brands, the main effect is modest protection that postpones but does not eliminate erosion. If coverage is unusually dense, the estate can sustain higher net pricing for longer.

---

What patent litigation or settlements affect Vivjoa’s generic risk?

Litigation outcomes that directly impact financial trajectory

For branded oral drugs, litigation and settlements can:

• Delay generic launch dates
• Reduce settlement scope through design-around or partial noninfringement
• Change expected “time to erosion” by months to years

However, specific Vivjoa litigation facts and case numbers are not provided in the prompt, so the assessment must remain structural rather than case-specific.

---

What generic entry risks exist for Vivjoa and when does revenue erosion typically accelerate?

Revenue erosion typically accelerates in three scenarios

1. Core compound protection expires with limited downstream patent layering
2. Orange Book listings thin out, making fewer patents “blocking”
3. A first generic launch triggers payer formulary downgrade and higher PA burden

For Vivjoa, the practical risk point is the date when the last broadly covering patents (especially those tied to the marketed dosage form) exit or weaken, and when PBMs can secure lower net costs through interchangeable supply.

---

Commercial trajectory outlook: how do market dynamics translate into revenue performance?

Base-case revenue dynamics

Vivjoa’s financial trajectory is expected to follow a pattern common to late entrants into crowded OAB class:

• Early ramp driven by prescribing uptake and limited access barriers
• Middle period shaped by payer placement, rebate intensity, and persistence
• Post-erosion pressure once competitive contracting and/or patent expiry reduces branded differentiation

Upside and downside levers

• Upside: sustained preferred formulary access, stable persistence, and reduced PA/step barriers across key payer contracts.
• Downside: faster net price compression from beta-3 peer competition and heightened payer controls as generic threat approaches.

Where revenue risk concentrates

Revenue risk concentrates in:

• major US payer segments that set formularies and net pricing
• cohorts with higher sensitivity to copay and prior authorization
• “repeat prescription” persistence rather than first-therapy adoption

---

Key Takeaways

• Vivjoa’s market dynamics are primarily payer-driven, with pricing and formulary tier determining how fast share and volume translate into net sales.
• The competitive baseline is mirabegron and ongoing antimuscarinic usage, which tends to pressure net pricing even if clinical adoption supports use.
• Financial erosion risk is structurally tied to Orange Book density and exclusivity duration; when blocking coverage thins, generic entry planning accelerates and branded revenue decays faster.
• Litigation and settlements can shift the timing of erosion, but the direction of effect is determined by remaining patent breadth at the time generic applicants are ready to launch.
• The strongest revenue lever is sustained “preferred” access that reduces PA and improves persistence.

---

FAQs

Which payer segments most influence Vivjoa’s net sales

Managed care plans using aggressive PBM contracting and preferred-tier policies generally drive utilization and net pricing outcomes.

Does Vivjoa face more formulary resistance than other OAB beta-3 agonists

Resistance typically depends on whether payers view it as a preferred beta-3 choice versus a secondary option to mirabegron.

What prescription patterns matter most for Vivjoa revenue durability

Persistence and refill behavior dominate lifetime revenue more than initial starts.

How does patent expiration timing affect Vivjoa’s forecast

Expiration calendars tied to Orange Book listings usually set the inflection points for pricing pressure and generic launch planning.

What commercial events signal upcoming erosion risk

Formulary tier downgrades, tighter step therapy, and copay program changes usually precede meaningful utilization declines.

---

References

No sources were provided in the prompt.